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Abstract
Background Tourette syndrome (TS) and persistent motor/vocal tic disorders are neurodevelopmental conditions characterised
by the chronic presence of motor and/or vocal tics. Patients with TS often present with co-morbid disorders, especially attention-
deficit and hyperactivity disorder (which tends to improve after childhood), and obsessive-compulsive disorder (which can
persist in adulthood). We set out to explore pharmacotherapy for tics in adult patients with TS and persistent motor/vocal tic
disorders, as well as its relationship with the presence of co-morbid conditions.
Methods We retrospectively reviewed the clinical characteristics and pharmacotherapy of 192 adult patients with TS (n = 187),
persistent motor tic disorder (n = 3) and persistent vocal tic disorder (n = 2) attending a specialist clinic in the UK.
Results Anti-dopaminergic medications (n = 65) and alpha-2-agonists (n = 50) were the most commonly prescribed pharmaco-
therapy for tic management. A sub-group analysis revealed that co-morbid obsessive-compulsive disorder and sub-threshold
obsessive-compulsive behaviours were significantly more common in patients treated with anti-dopaminergic medications than
patients taking alpha-2-agonists (p = 0.013 and p = 0.047, respectively).
Conclusions The use of pharmacotherapy options for tic management observed at a specialist clinic for adults with TS reflects
guideline recommendations. We found that the presence of co-morbid obsessive-compulsive disorder/behaviours correlates with
the choice of anti-dopaminergic medications over alpha-2-agonists, in line with available evidence on the efficacy of anti-
dopaminergic medications for the treatment of specific tic–related behavioural symptoms.
Keywords Tourette syndrome . Tics . Pharmacotherapy . Guidelines . Anti-dopaminergic medications . Alpha-2 agonist
medications
Introduction
Tourette syndrome (TS) is a neurodevelopmental disorder
characterised by the presence of both motor and vocal tics
with a chronic course [1]. Individuals with chronic motor tics
only fulfil diagnostic criteria for persistent motor tic disorder,
whereas those with chronic vocal tics only are diagnosed with
persistent vocal tic disorder. TS is frequently associated with
co-morbid conditions, especially attention-deficit and hyper-
activity disorder (ADHD), which tends to improve after child-
hood, and obsessive-compulsive disorder (OCD), which often
persists in adulthood [1].
The recently published American Academy of Neurology
guidelines on the assessment and treatment of tics in patients
with TS and other chronic tic disorders recommend the use of
alpha-2-agonists and anti-dopaminergic medications as phar-
macotherapy of choice for the treatment of tics [2]. However,
little is known about current practice in the use of pharmaco-
therapy for tic disorders in adults and how closely this practice
aligns with evidence-based guidelines. In the present study,
we set out to explore pharmacotherapy for tics in adult patients
with TS and persistent motor/vocal tic disorders, as well as its
relationship with the presence of co-morbid conditions.
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Methods
Participants
We recruited 192 consecutive patients attending the spe-
cialist Tourette Syndrome Clinic, Department of
Neuropsychiatry, National Centre for Mental Health,
Birmingham, UK. All patients fulfilled current diagnos-
tic criteria for TS or other chronic tic disorders. Patients
under 16 years of age, with limited understanding of
English and with severe autism spectrum disorder/
learning disability were excluded from the study.
Clinical assessment
Each patient underwent a comprehensive clinical assess-
ment using the National Hospital Interview Schedule
(NHIS) for TS [3]. The NHIS is a detailed semi-
structured interview schedule covering personal and fam-
ily histories, as well as demographic details. The clinical
variables systematically collected for this study included
age at interview, age at first tic onset, disease duration,
family history of tics, psychiatric co-morbidities and phar-
macotherapy. The Diagnostic Confidence Index (DCI)
was used to rate the clinician’s confidence in diagnosing
TS, according to the clinical characteristics of the tics and
the presence of specific complex tics [4]. The DCI is a
clinician-rated measure of lifetime likelihood of TS diag-
nosis in patients presenting with tics. The DCI score is
expressed as a percentage, with higher scores indicating
higher confidence that the patient has TS. Tic severity was
measured using the Yale Global Tic Severity Scale
(YGTSS), a clinician-rated scale assessing the severity
of both motor and vocal tics across five different domains:
number, frequency, intensity, complexity and interference
[5, 6]. Each domain is scored 0–5 and severity scores are
separately calculated for motor and vocal tics by summing
together the individual domain scores. Finally, the com-
bined motor and vocal tic severity scores produce a total
tic severity score. An additional measure of overall im-
pairment is scored 0–50. These two scores are combined
to produce the total YGTSS score, ranging from 0 to 100,
with higher scores indicating increased tic severity.
Statistical analysis
All statistical analyses were conducted using parametric test-
ing on continuous variables that were normally distributed and
non-parametric testing on continuous variables that were not
normally distributed. The chi-square test was used for non-
continuous variables.
Results
Out of the 192 adult patients in our clinical sample, 187 had a
diagnosis of TS, 3 persistent motor tic disorder and 2 persis-
tent vocal tic disorder. The demographic and clinical charac-
teristics of the sample are shown in Table 1.
About two thirds of the patients (66.7%) were on some
form of pharmacotherapy for their tics (Table 2). Anti-
dopaminergic medications (n = 65) and alpha-2-agonists
(n = 50) were the most commonly prescribed pharmacological
classes. All patients taking alpha-2 agonists were prescribed
clonidine, the most commonly used tic-suppressing
medication.
A sub-group analysis compared the clinical characteristics
of patients taking anti-dopaminergic medications only (n =
55) with those of patients taking alpha-2-agonists only (n =
40). The only significant difference between the two sub-
groups was identified when analysing the presence of co-mor-
bidities: patients with OCDwere more likely to be taking anti-
dopaminergic medications than alpha-2-agonists (77.8% ver-
sus 22.2%, chi-square = 6.117, p = 0.013). The same differ-
ence was observed with sub-threshold obsessive-compulsive
behaviours (65.1% versus 34.9%, chi-square = 3.960, p =
0.047).
Discussion
The use of pharmacotherapy for tic management observed in a
large and representative clinical sample of adult patients with
Table 1 Demographic and clinical characteristics of the sample of
patients with Tourette syndrome and other chronic tic disorders (n = 192)
Male gender (n, %) 134 (69.8)
Age (median, range) 24 (16–68)
Age at first tic onset (mean, SD) 8.4 (4.1)
Family history of tics (n, %) 101 (52.6)
OCD (n, %) 49 (25.5)
OCB (n, %) 130 (67.7)
ADHD (n, %) 56 (29.2)
ASD (Asperger syndrome) (n, %) 23 (12.0)
Mild LD (n, %) 14 (7.3)
Depression (n, %) 71 (37.0)
Anxiety (n, %) 34 (17.7)
DCI (mean, SD) 70.2 (18.3)
YGTSS tic severity score (mean, SD) 29.3 (8.3)
YGTSS impairment score (mean, SD) 26.0 (8.6)
YGTSS total score (mean, SD) 55.4 (14.6)
Abbreviations. OCD, obsessive-compulsive disorder; OCB, obsessive-
compulsive behaviours; ADHD, attention-deficit and hyperactivity disor-
der; ASD, autism spectrum disorder; LD, learning difficulty; DCI,
Diagnostic Confidence Index; YGTSS, Yale Global Tic Severity Scale
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TS and other chronic tic disorders reflects current guideline
recommendations [2]. The DCI scores in our sample are in
line with the scores reported by patients seen at specialist
clinics for the treatment of tic disorders, indicating high diag-
nostic confidence [4]. Our findings are also in line with the
results of a recent study on pharmacological prescriptions in
Canadian children with tic disorders [7]: the growing use of
clonidine and aripiprazole appears to be driven by emerging
evidence supporting their efficacy on tics, as well as their
safety [8, 9]. Interestingly, recommendations for first-
generation anti-dopaminergic agents such as haloperidol and
pimozide were comparatively limited, likely due to the greater
adverse effects (especially sedation, weight gain,
hyperprolactinaemia and extrapyramidal symptoms) associat-
ed with these medications [9]. Likewise, the wider use of
risperidone compared with pimozide reflected the recent rec-
ommendations about its different tolerability pattern, wider
spectrum of action and potentially higher certainty in the ef-
fect estimate [9].
We found that the presence of co-morbid OCD/obsessive-
compulsive behaviours correlates with the choice of anti-
dopaminergic medications over alpha-2-agonists, in line with
available evidence on the efficacy of anti-dopaminergic med-
ications for the treatment of specific tic–related behavioural
symptoms. In a recent study on adults with TS, aripiprazole
significantly improved OCD and showed a trend toward im-
provement of other behavioural co-morbidities [10]. In the
same study, patients with TS and co-morbid OCD tended to
decide in favour of pharmacotherapy, suggesting that the
decision-making process for or against medical treatment
could be influenced by the presence of specific behavioural
co-morbidities. Moreover, there is some evidence that patients
with both TS and tic-related OCD do not respond as well to
serotonergic medication (first-line pharmacotherapy for OCD)
compared with patients with primary OCD only [2]. It can be
hypothesised that the beneficial effects of aripiprazole on both
tics and tic-related OCD are related to this medication’s adap-
tive pharmacological profile, which exhibits an influence on
multiple neurotransmitter systems in addition to dopaminergic
pathways, as well as to shared mechanisms underpinning the
expression of both tics and tic-related obsessive-compulsive
behaviours.
The main limitations of the present study include its retro-
spective approach and referral bias, as participants were re-
cruited from a tertiary referral centre and may therefore not be
representative of the wider community. Future research is
needed to fully understand how the phenotypic heterogeneity
of patients with TS and other chronic tic disorders affects
pharmacotherapy across the lifespan.
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